Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
Authors:
Open Access
- 4 November 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Abstract
To report the early efficacy and safety outcomes of treatment with intravitreal injections of brolucizumab (IVT-B) in patients presenting neovascular age-related macular degeneration (nAMD) in a tertiary clinical setting. A retrospective case series of patients that received IVT-B with a minimum of two injections performed and at least 4 weeks of follow-up after last injection. Nineteen eyes of 19 patients were included. The number of IVT-B performed for the whole cohort was 58 injections; the mean number of IVT-B per patient was 3.0 ± 1.0 (range 2–6); the mean follow-up time was 14.4 ± 9.0 weeks. Mean baseline best-corrected visual acuity was 0.4 ± 0.4 logMAR and at the last follow-up was 0.4 ± 0.6 logMAR (p = 0.778). All eyes showed a reduction in retinal thickness, with the central macular thickness being 470 ± 151 μm at baseline and 360 ± 144 μm at the last follow-up (p = 0.001). Intra-retinal fluid was present at baseline in 12 eyes (63%) and in three eyes (16%) at the last follow-up (p = 0.065). Sub-retinal fluid was present at baseline in 17 eyes (89%) and at the last follow-up in three eyes (16%, p = 0.011). Pigment epithelium detachment was apparent in the 16 eyes (84%) at baseline and was still present in 14 eyes (73%, p = 0.811). One adverse event of intraocular inflammation was reported. In conclusion, our short-term experience showed that brolucizumab was highly effective in restoring the anatomy and in stabilizing the visual acuity of eyes with nAMD. Its safety profile should be evaluated carefully and needs further investigations.Keywords
This publication has 36 references indexed in Scilit:
- Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular DegenerationOphthalmology, 2018
- Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular DegenerationOphthalmology, 2018
- A systematic review to assess the ‘treat-and-extend’ dosing regimen for neovascular age-related macular degeneration using ranibizumabEye, 2017
- Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments TrialsOphthalmology, 2017
- Geo-Epidemiology of Age-Related Macular Degeneration: New Clues Into the PathogenesisAmerican Journal of Ophthalmology, 2016
- Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)British Journal of Ophthalmology, 2014
- Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments TrialsOphthalmology, 2014
- Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International WorkshopAmerican Journal of Ophthalmology, 2005
- Biodegradable microspheres for the intravitreal administration of acyclovir: in vitro/in vivo evaluationEuropean Journal of Pharmaceutical Sciences, 1997
- Standardizatlon of Vitreal inflammatory Activity in Intermediate and Posterior UveitisOphthalmology, 1985